|
1
|
O’Byrne KJ, Barr MP and Gray SG: The role
of epigenetics in resistance to Cisplatin chemotherapy in lung
cancer. Cancers (Basel). 3:1426–1453. 2011. View Article : Google Scholar
|
|
2
|
Zhuang H, Jiang W, Zhang X, Qiu F, Gan Z,
Cheng W, Zhang J, Guan S, Tang B, Huang Q, et al: Suppression of
HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced
apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L
expressions. J Mol Med (Berl). 91:219–235. 2013. View Article : Google Scholar
|
|
3
|
Lv XB, Liu L, Cheng C, Yu B, Xiong L, Hu
K, Tang J, Zeng L and Sang Y: SUN2 exerts tumor suppressor
functions by suppressing the Warburg effect in lung cancer. Sci
Rep. 5:179402015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boulikas T: Molecular mechanisms of
cisplatin and its liposomally encapsulated form, Lipoplatin.
Lipoplatin as a chemotherapy and antiangiogenesis drug. Cancer Biol
Ther. 5:351–376. 2007.
|
|
5
|
Lin Y, Wang Z, Liu L and Chen L: Akt is
the downstream target of GRP78 in mediating cisplatin resistance in
ER stress-tolerant human lung cancer cells. Lung Cancer.
71:291–297. 2011. View Article : Google Scholar
|
|
6
|
Fuertes MA, Alonso C and Pérez JM:
Biochemical modulation of cisplatin mechanisms of action:
Enhancement of antitumor activity and circumvention of drug
resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar
|
|
7
|
Bottazzi B, Inforzato A, Messa M,
Barbagallo M, Magrini E, Garlanda C and Mantovani A: The pentraxins
PTX3 and SAP in innate immunity, regulation of inflammation and
tissue remodelling. J Hepatol. 64:1416–1427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balhara J, Koussih L, Zhang J and Gounni
AS: Pentraxin 3: An immuno-regulator in the lungs. Front Immunol.
4:1272013. View Article : Google Scholar
|
|
9
|
Inforzato A, Rivieccio V, Morreale AP,
Bastone A, Salustri A, Scarchilli L, Verdoliva A, Vincenti S, Gallo
G, Chiapparino C, et al: Structural characterization of PTX3
disulfide bond network and its multimeric status in cumulus matrix
organization. J Biol Chem. 283:10147–10161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Inforzato A, Reading PC, Barbati E,
Bottazzi B, Garlanda C and Mantovani A: The ‘sweet’ side of a long
pentraxin: How glycosylation affects PTX3 functions in innate
immunity and inflammation. Front Immunol. 3:4072013. View Article : Google Scholar
|
|
11
|
EL-Attar HA, Abaza MM, Gaber EW and
EL-sharkawy RM: Serum profiles of pentraxin-3 and high sensitivity
C - reactive protein in patients with chronic kidney disease
treated with or without hemodialysis. J Nephrol Ther. 7:12017.
|
|
12
|
Locatelli M, Ferrero S, Martinelli
Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S, Bello L,
Valentino S, Barbati E, Nebuloni M, et al: The long pentraxin PTX3
as a correlate of cancer-related inflammation and prognosis of
malignancy in gliomas. J Neuroimmunol. 260:99–106. 2013. View Article : Google Scholar
|
|
13
|
Willeke F, Assad A, Findeisen P, Schromm
E, Grobholz R, von Gerstenbergk B, Mantovani A, Peri S, Friess HH,
Post S, et al: Overexpression of a member of the pentraxin family
(PTX3) in human soft tissue liposarcoma. Eur J Cancer.
42:2639–2646. 2006. View Article : Google Scholar
|
|
14
|
Stallone G, Cormio L, Netti GS, Infante B,
Selvaggio O, Fino GD, Ranieri E, Bruno F, Prattichizzo C,
Sanguedolce F, et al: Pentraxin 3: A novel biomarker for predicting
progression from prostatic inflammation to prostate cancer. Cancer
Res. 74:4230–4238. 2014. View Article : Google Scholar
|
|
15
|
Diamandis EP, Goodglick L, Planque C and
Thornquist MD: Pentraxin-3 is a novel biomarker of lung carcinoma.
Clin Cancer Res. 17:2395–2399. 2011. View Article : Google Scholar
|
|
16
|
Choi B, Lee EJ, Song DH, Yoon SC, Chung
YH, Jang Y, Kim SM, Song Y, Kang SW, Yoon SY, et al: Elevated
Pentraxin 3 in bone metastatic breast cancer is correlated with
osteolytic function. Oncotarget. 5:481–492. 2014. View Article : Google Scholar :
|
|
17
|
Argani H, Ghorbanihaghjo A, Panahi G,
Rashtchizadeh N, Safa J and Meimand SM: Serum Fetuin-A and
Pentraxin3 in hemodialysis and renal transplant patients. Clin
Biochem. 45:775–779. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chi JY, Hsiao YW, Li CF, Lo YC, Lin ZY,
Hong JY, Liu YM, Han X, Wang SM, Chen BK, et al: Targeting
chemotherapy-induced PTX3 in tumor stroma to prevent the
progression of drug-resistant cancers. Oncotarget. 6:23987–24001.
2015. View Article : Google Scholar
|
|
19
|
Vasconcelos-Dos-Santos A, Oliveira IA,
Lucena MC, Mantuano NR, Whelan SA, Dias WB and Todeschini AR:
Biosynthetic machinery involved in aberrant glycosylation:
Promising targets for developing of drugs against cancer. Front
Oncol. 5:1382015. View Article : Google Scholar
|
|
20
|
Song EY, Kang SK, Lee YC, Park YG, Chung
TH, Kwon DH, Byun SM and Kim CH: Expression of bisecting
N-acetylglucosaminyltransferase-III in human hepatocarcinoma
tissues, fetal liver tissues, and hepatoma cell lines of Hep3B and
HepG2. Cancer Invest. 19:799–807. 2001. View Article : Google Scholar
|
|
21
|
Mori S, Aoyagi Y, Yanagi M, Suzuki Y and
Asakura H: Serum N-acetylglucosaminyltransferase III activities in
hepatocellular carcinoma. J Gastroenterol Hepatol. 13:610–619.
1998. View Article : Google Scholar
|
|
22
|
Dube DH and Bertozzi CR: Glycans in cancer
and inflammation - potential for therapeutics and diagnostics. Nat
Rev Drug Discov. 4:477–488. 2005. View
Article : Google Scholar
|
|
23
|
Chatterjee BP, Mondal G and Chatterjee U:
Glycosylation of acute phase proteins: A promising disease
biomarker. Proc Natl Acad Sci, India - Sect B:Biol Sci. 84:865–874.
2014. View Article : Google Scholar
|
|
24
|
Reticker-Flynn NE and Bhatia SN: Aberrant
glycosylation promotes lung cancer metastasis through adhesion to
galectins in the metastatic niche. Cancer Discov. 5:168–181. 2015.
View Article : Google Scholar
|
|
25
|
Contessa JN, Bhojani MS, Freeze HH,
Rehemtulla A and Lawrence TS: Inhibition of N-linked glycosylation
disrupts receptor tyrosine kinase signaling in tumor cells. Cancer
Res. 68:3803–3809. 2008. View Article : Google Scholar
|
|
26
|
de Freitas Junior JCM and Morgado-Díaz JA:
The role of N-glycans in colorectal cancer progression: Potential
biomarkers and therapeutic applications. Oncotarget. 7:19395–19413.
2016.
|
|
27
|
Han X, Zhang X, Li H, Huang S, Zhang S,
Wang F and Shi Y: Tunicamycin enhances the antitumor activity of
trastuzumab on breast cancer in vitro and in vivo. Oncotarget.
6:38912–38925. 2015. View Article : Google Scholar
|
|
28
|
Ahsan A, Hiniker SM, Ramanand SG, Nyati S,
Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS and Nyati MK:
Role of epidermal growth factor receptor degradation in
cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res.
70:2862–2869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banerjee A, Lang JY, Hung MC, Sengupta K,
Banerjee SK, Baksi K and Banerjee DK: Unfolded protein response is
required in nu/nu mice microvasculature for treating breast tumor
with tunicamycin. J Biol Chem. 286:29127–29138. 2011. View Article : Google Scholar
|
|
30
|
Planque C, Kulasingam V, Smith CR, Reckamp
K, Goodglick L and Diamandis EP: Identification of five candidate
lung cancer biomarkers by proteomics analysis of conditioned media
of four lung cancer cell lines. Mol Cell Proteomics. 8:2746–2758.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kondo S, Ueno H, Hosoi H, Hashimoto J,
Morizane C, Koizumi F, Tamura K and Okusaka T: Clinical impact of
pentraxin family expression on prognosis of pancreatic carcinoma.
Br J Cancer. 109:739–746. 2013. View Article : Google Scholar
|
|
32
|
O’Connor SE and Imperiali B: Modulation of
protein structure and function by asparagine-linked glycosylation.
Chem Biol. 3:803–812. 1996. View Article : Google Scholar
|
|
33
|
Häuselmann I and Borsig L: Altered
tumor-cell glycosylation promotes metastasis. Front Oncol.
4:282014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kudo T, Nakagawa H, Takahashi M, Hamaguchi
J, Kamiyama N, Yokoo H, Nakanishi K, Nakagawa T, Kamiyama T,
Deguchi K, et al: N-glycan alterations are associated with drug
resistance in human hepatocellular carcinoma. Mol Cancer. 6:322007.
View Article : Google Scholar :
|
|
35
|
Tafani M, Russo A, Di Vito M, Sale P,
Pellegrini L, Schito L, Gentileschi S, Bracaglia R, Marandino F,
Garaci E, et al: Up-regulation of pro-inflammatory genes as
adaptation to hypoxia in MCF-7 cells and in human mammary invasive
carcinoma microenvironment. Cancer Sci. 101:1014–1023. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li WP, Zuber C, Heitz PU and Roth J:
Cytochemical staining for beta 1,6 branching of asparagine-linked
oligosaccharides in variants of metastatic human colon carcinoma
cells. Am J Pathol. 145:470–480. 1994.
|
|
37
|
Saldova R, Fan Y, Fitzpatrick JM, Watson
RW and Rudd PM: Core fucosylation and alpha2-3 sialylation in serum
N-glycome is significantly increased in prostate cancer comparing
to benign prostate hyperplasia. Glycobiology. 21:195–205. 2011.
View Article : Google Scholar
|
|
38
|
Liu L, Yan B, Huang J, Gu Q, Wang L, Fang
M, Jiao J and Yue X: The identification and characterization of
novel N-glycan-based biomarkers in gastric cancer. PLoS One.
8:e778212013. View Article : Google Scholar :
|
|
39
|
Saldova R, Reuben JM, Abd Hamid UM, Rudd
PM and Cristofanilli M: Levels of specific serum N-glycans identify
breast cancer patients with higher circulating tumor cell counts.
Ann Oncol. 22:1113–1119. 2011. View Article : Google Scholar
|
|
40
|
Li L, Khan MN, Li Q, Chen X, Wei J, Wang
B, Cheng JW, Gordon JR and Li F: G31P, CXCR1/2 inhibitor, with
cisplatin inhibits the growth of mice hepatocellular carcinoma and
mitigates high dose cisplatin-induced nephrotoxicity. Oncol Rep.
33:751–757. 2015. View Article : Google Scholar
|
|
41
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar
|
|
42
|
Tanida S, Mizoshita T, Ozeki K, Tsukamoto
H, Kamiya T, Kataoka H, Sakamuro D and Joh T: Mechanisms of
cisplatin-induced apoptosis and of cisplatin sensitivity: Potential
of BIN1 to act as a potent predictor of cisplatin sensitivity in
gastric cancer treatment. Int J Surg Oncol. 2012.862879:2012.
|
|
43
|
Liu X, Nie H, Zhang Y, Yao Y, Maitikabili
A, Qu Y, Shi S, Chen C and Li Y: Cell surface-specific N-glycan
profiling in breast cancer. PLoS One. 8:e727042013. View Article : Google Scholar
|
|
44
|
Ferreira JA, Peixoto A, Neves M, Gaiteiro
C, Reis CA, Assaraf YG and Santos LL: Mechanisms of cisplatin
resistance and targeting of cancer stem cells: Adding glycosylation
to the equation. Drug Resist Updat. 24:34–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Peiris D, Spector AF, Lomax-Browne H,
Azimi T, Ramesh B, Loizidou M, Welch H and Dwek MV: Cellular
glycosylation affects Herceptin binding and sensitivity of breast
cancer cells to doxorubicin and growth factors. Sci Rep.
7:430062017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hiss DC, Gabriels GA and Folb PI:
Combination of tunicamycin with anticancer drugs synergistically
enhances their toxicity in multidrug-resistant human ovarian
cystadenocarcinoma cells. Cancer Cell Int. 7:52007. View Article : Google Scholar
|
|
47
|
Noda I, Fujieda S, Seki M, Tanaka N,
Sunaga H, Ohtsubo T, Tsuzuki H, Fan GK and Saito H: Inhibition of
N-linked glycosylation by tunicamycin enhances sensitivity to
cisplatin in human head-and-neck carcinoma cells. Int J Cancer.
80:279–284. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen W, Li Z, Bai L and Lin Y: NF-kappaB,
a mediator for lung carcinogenesis and a target for lung cancer
prevention and therapy. Front Biosci. 16:1172–1185. 2011.
View Article : Google Scholar
|
